Bi-specific fusion proteins

US11814443B2 · kind B2 · utility

Assignee

• Silver Creek Pharmaceuticals, Inc. · US

Inventors

• Ulrik Nielsen · Quincy, US
• Thomas Wickham · Groton, US
• Birgit Schoeberl · Cambridge, US
• Brian Harms · Brookline, US
• Bryan Linggi · Richland, US
• Matthew Onsum · Corona, US
• Byron DeLaBarre · Arlington, US
• Shaun M. Lippow · Somerville, US

Key dates

• Filing date: Mar 25, 2021
• Grant date: Nov 14, 2023
• Expiry date: Dec 25, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/80
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.